Your browser doesn't support javascript.
loading
Efficacy of escalating therapy with brentuximab vedotin-AVD in advanced stage Hodgkin lymphoma patients with positive interim positron emission tomography after ABVD.
Martínez, Carmen; Carcelero, Esther; Gutiérrez, Antonio; Sancho, Esther; Martí-Tutusaus, Josep Maria; Magnano, Laura; Mozas, Pablo; Fernández-Avilés, Francesc; Antelo, María Gabriela; Setoain, Xavier; Rodríguez, Sonia; Esteve, Jordi.
Affiliation
  • Martínez C; Hematology Department, Institute of Cancer and Blood Diseases (ICAMS), Hospital Clínic of Barcelona, Barcelona, Spain.
  • Carcelero E; August Pi i Sunyer Biomedical Research Institute-IDIBAPS, Barcelona, Spain.
  • Gutiérrez A; Farmacology Department, Center of Biomedic Diagnosis, Hospital Clínic of Barcelona, Barcelona, Spain.
  • Sancho E; Hematology Department, Hospital Universitario Son Espases, Palma de Mallorca, Spain.
  • Martí-Tutusaus JM; Hematology Department, Hospital de Granollers, Barcelona, Spain.
  • Magnano L; Hematology Department, Hospital Mutua de Terrassa, Barcelona, Spain.
  • Mozas P; Hematology Department, Institute of Cancer and Blood Diseases (ICAMS), Hospital Clínic of Barcelona, Barcelona, Spain.
  • Fernández-Avilés F; Hematology Department, Institute of Cancer and Blood Diseases (ICAMS), Hospital Clínic of Barcelona, Barcelona, Spain.
  • Antelo MG; Hematology Department, Institute of Cancer and Blood Diseases (ICAMS), Hospital Clínic of Barcelona, Barcelona, Spain.
  • Setoain X; August Pi i Sunyer Biomedical Research Institute-IDIBAPS, Barcelona, Spain.
  • Rodríguez S; Radiation Oncology Department, Institute of Cancer and Blood Diseases (ICAMS), Hospital Clinic Barcelona, Barcelona, Spain.
  • Esteve J; August Pi i Sunyer Biomedical Research Institute-IDIBAPS, Barcelona, Spain.
Hematol Oncol ; 42(5): e3299, 2024 Sep.
Article in En | MEDLINE | ID: mdl-39132926
ABSTRACT
Patients with advanced-stage Hodgkin lymphoma treated with ABVD who have a positive interim FDG-PET (iPET) have a poor prognosis. Escalation to BEACOPP has been shown to improve progression-free survival (PFS). However, randomized trials are lacking to determine the best strategy for intensification. We report on A-AVD escalation treatment outcomes for 15 iPET-positive patients post-ABVD. Overall response and complete response rates were 80% and 60%, respectively. Four patients underwent salvage therapy followed by autologous stem cell transplantation. At a median 17-month follow-up, all patients are alive, 87% in complete remission, and 1-year PFS was 57.8%. For patients ineligible for BEACOPP due to age, comorbidities, or preference, A-AVD escalation may be a viable alternative.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Vinblastine / Bleomycin / Hodgkin Disease / Antineoplastic Combined Chemotherapy Protocols / Doxorubicin / Dacarbazine / Positron-Emission Tomography / Brentuximab Vedotin Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Hematol Oncol Year: 2024 Document type: Article Affiliation country: Country of publication:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Vinblastine / Bleomycin / Hodgkin Disease / Antineoplastic Combined Chemotherapy Protocols / Doxorubicin / Dacarbazine / Positron-Emission Tomography / Brentuximab Vedotin Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Hematol Oncol Year: 2024 Document type: Article Affiliation country: Country of publication: